While the perception around cannabis has started shifting, it still remains under the label of a
We live in an era of personalisation, and it is no different when it comes to medicine. Precision medicine remains a hot topic in the medical industry, especially in cancer treatment, offering a tailored approach to address the unique needs and symptoms of each patient. We can take this same path with medical cannabis, potentially inciting less harm to the body. Marrying this concept with emerging technology, such as artificial intelligence (AI) and big data, affords an even greater level of precision for those who need it most.
The first step to make this concept a reality is overcoming the stigma associated with cannabis. While the perception around cannabis has started shifting from a recreational gateway drug with no medicinal value to one with the potential to improve the lives of those living with chronic or terminal illnesses, cannabis still remains under the label of a
Although most scientists agree on cannabis’ medical potential, in most countries, legislation lags behind the science, leaving many physicians ill-equipped with the data and tools needed to justify their prescriptions and also leaving patients at a loss. To prescribe correctly, physicians need clinical data around proper dosing, formulation and means of administration, as well as intel on how side effects vary among individual patients. The schedule I classification inhibits necessary cannabis research. To address the desperate need for additional research, many companies have turned to conducting their studies outside the U.S. borders. This is a major missed opportunity for the United States.
Despite these hurdles, technology is going to play a major role in the personalisation of medical cannabis. In our
For Full Article follow link at the top of this page.